Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03610971
Title Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

chronic myeloid leukemia

Therapies

Nilotinib + Ruxolitinib

Imatinib + Ruxolitinib

Bosutinib + Ruxolitinib

Dasatinib + Ruxolitinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.